200 related articles for article (PubMed ID: 16129783)
1. Regulation of ubiquitin ligase dynamics by the nucleolus.
Mekhail K; Khacho M; Carrigan A; Hache RR; Gunaratnam L; Lee S
J Cell Biol; 2005 Aug; 170(5):733-44. PubMed ID: 16129783
[TBL] [Abstract][Full Text] [Related]
2. HIF activation by pH-dependent nucleolar sequestration of VHL.
Mekhail K; Gunaratnam L; Bonicalzi ME; Lee S
Nat Cell Biol; 2004 Jul; 6(7):642-7. PubMed ID: 15181450
[TBL] [Abstract][Full Text] [Related]
3. PML regulates p53 stability by sequestering Mdm2 to the nucleolus.
Bernardi R; Scaglioni PP; Bergmann S; Horn HF; Vousden KH; Pandolfi PP
Nat Cell Biol; 2004 Jul; 6(7):665-72. PubMed ID: 15195100
[TBL] [Abstract][Full Text] [Related]
4. Do VHL and HIF-1 mirror p53 and Mdm-2? Degradation-transactivation loops of oncoproteins and tumor suppressors.
Blagosklonny MV
Oncogene; 2001 Jan; 20(3):395-8. PubMed ID: 11313969
[TBL] [Abstract][Full Text] [Related]
5. EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors.
Cai QL; Knight JS; Verma SC; Zald P; Robertson ES
PLoS Pathog; 2006 Oct; 2(10):e116. PubMed ID: 17069461
[TBL] [Abstract][Full Text] [Related]
6. Molecular cloning and characterization of the von Hippel-Lindau-like protein.
Qi H; Gervais ML; Li W; DeCaprio JA; Challis JR; Ohh M
Mol Cancer Res; 2004 Jan; 2(1):43-52. PubMed ID: 14757845
[TBL] [Abstract][Full Text] [Related]
7. Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein.
Yu F; White SB; Zhao Q; Lee FS
Cancer Res; 2001 May; 61(10):4136-42. PubMed ID: 11358837
[TBL] [Abstract][Full Text] [Related]
8. Immobilization of proteins in the nucleolus by ribosomal intergenic spacer noncoding RNA.
Audas TE; Jacob MD; Lee S
Mol Cell; 2012 Jan; 45(2):147-57. PubMed ID: 22284675
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
Tanimoto K; Makino Y; Pereira T; Poellinger L
EMBO J; 2000 Aug; 19(16):4298-309. PubMed ID: 10944113
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
12. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
Honda R; Yasuda H
EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
[TBL] [Abstract][Full Text] [Related]
13. Role of the C-terminal alpha-helical domain of the von Hippel-Lindau protein in its E3 ubiquitin ligase activity.
Lewis MD; Roberts BJ
Oncogene; 2004 Mar; 23(13):2315-23. PubMed ID: 14691445
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.
An J; Rettig MB
Mol Cell Biol; 2005 Sep; 25(17):7546-56. PubMed ID: 16107702
[TBL] [Abstract][Full Text] [Related]
15. The contribution of the acidic domain of MDM2 to p53 and MDM2 stability.
Argentini M; Barboule N; Wasylyk B
Oncogene; 2001 Mar; 20(11):1267-75. PubMed ID: 11313871
[TBL] [Abstract][Full Text] [Related]
16. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.
Chen D; Kon N; Li M; Zhang W; Qin J; Gu W
Cell; 2005 Jul; 121(7):1071-83. PubMed ID: 15989956
[TBL] [Abstract][Full Text] [Related]
17. Nucleolar Arf sequesters Mdm2 and activates p53.
Weber JD; Taylor LJ; Roussel MF; Sherr CJ; Bar-Sagi D
Nat Cell Biol; 1999 May; 1(1):20-6. PubMed ID: 10559859
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
19. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function.
Korgaonkar C; Hagen J; Tompkins V; Frazier AA; Allamargot C; Quelle FW; Quelle DE
Mol Cell Biol; 2005 Feb; 25(4):1258-71. PubMed ID: 15684379
[TBL] [Abstract][Full Text] [Related]
20. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
